Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Benjamin Farahnik, Kourosh Beroukhim, Michael Abrouk, et al.
Dermatology and Therapy (2016) Vol. 6, Iss. 2, pp. 111-124
Open Access | Times Cited: 134

Showing 1-25 of 134 citing articles:

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Clinical Reviews in Allergy & Immunology (2018) Vol. 55, Iss. 3, pp. 379-390
Open Access | Times Cited: 590
Interleukin 17 is a chief orchestrator of immunity
Marc Veldhoen
Nature Immunology (2017) Vol. 18, Iss. 6, pp. 612-621
Closed Access | Times Cited: 418
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 754-766
Closed Access | Times Cited: 407
Antibodies to watch in 2018
Hélène Kaplon, Janice M. Reichert
mAbs (2018) Vol. 10, Iss. 2, pp. 183-203
Open Access | Times Cited: 232
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)
Kevin Winthrop, Xavier Mariette, J.T. Silva, et al.
Clinical Microbiology and Infection (2018) Vol. 24, pp. S21-S40
Open Access | Times Cited: 223
Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders
Patrizia Fasching, Martin Stradner, W. Graninger, et al.
Molecules (2017) Vol. 22, Iss. 1, pp. 134-134
Open Access | Times Cited: 218
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B. Gordon, Peter Foley, James G. Krueger, et al.
The Lancet (2021) Vol. 397, Iss. 10273, pp. 475-486
Closed Access | Times Cited: 204
Current Developments in the Immunology of Psoriasis.
Franziska Grän, Andreas Kerstan, Edgar Serfling, et al.
The Yale Journal of Biology and Medicine (2020) Vol. 93, Iss. 1, pp. 97-110
Closed Access | Times Cited: 173
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
Esther von Stebut, Wolf‐­Henning Boehncke, Kamran Ghoreschi, et al.
Frontiers in Immunology (2020) Vol. 10
Open Access | Times Cited: 163
The role of inflammation in autoimmune disease: a therapeutic target
Yu Xiang, Mingxue Zhang, D.Y. Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 52
The Promising Role of Polyphenols in Skin Disorders
Mohd Farhan
Molecules (2024) Vol. 29, Iss. 4, pp. 865-865
Open Access | Times Cited: 23
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
Andrew Blauvelt, Kim Papp, Alice B. Gottlieb, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 6, pp. 1348-1358
Open Access | Times Cited: 143
Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups
Bridget Kaufman, Andrew Alexis
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 405-423
Closed Access | Times Cited: 109
Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis
Aoife McGinley, Sarah C. Edwards, Mathilde Raverdeau, et al.
Journal of Autoimmunity (2018) Vol. 87, pp. 97-108
Closed Access | Times Cited: 107
IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa
Jean M. Fletcher, Barry Moran, Andreea Petrasca, et al.
Clinical & Experimental Immunology (2020) Vol. 201, Iss. 2, pp. 121-134
Open Access | Times Cited: 106
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
Caleb Jeon, Sahil Sekhon, Di Yan, et al.
Human Vaccines & Immunotherapeutics (2017) Vol. 13, Iss. 10, pp. 2247-2259
Open Access | Times Cited: 103
The Role of IL-17 in Protection against Mucosal Candida Infections
Bemnet Mengesha, Heather R. Conti
Journal of Fungi (2017) Vol. 3, Iss. 4, pp. 52-52
Open Access | Times Cited: 101
In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine
Meng Xu, Jingwen Deng, Kaikun Xu, et al.
Theranostics (2019) Vol. 9, Iss. 9, pp. 2475-2488
Open Access | Times Cited: 99
Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
Melinda Gooderham, Kim Papp, Charles Lynde
Journal of the European Academy of Dermatology and Venereology (2018) Vol. 32, Iss. 7, pp. 1111-1119
Open Access | Times Cited: 98
Cytokines in uveitis
Jessica E. Weinstein, Kathryn L. Pepple
Current Opinion in Ophthalmology (2018) Vol. 29, Iss. 3, pp. 267-274
Open Access | Times Cited: 97
CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17–Mediated Psoriasiform Skin Inflammation In Vivo
Mark Mellett, Barbara Meier, Deepa Mohanan, et al.
Journal of Investigative Dermatology (2018) Vol. 138, Iss. 9, pp. 2010-2023
Open Access | Times Cited: 84
Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics
Robert G. Petit, Amanda Cano, A. Ortiz, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4983-4983
Open Access | Times Cited: 84
A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer
Pablo Vieyra-Garcia, Peter Wolf
Pharmacology & Therapeutics (2020) Vol. 222, pp. 107784-107784
Closed Access | Times Cited: 72
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
Matteo Megna, Luca Potestio, Elisa Camela, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 9
Open Access | Times Cited: 43
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top